TDA - while I respect your enthusiasm - I think you need to temper your optimism with a bit of commercial pragmatism.
To gain a 30% market share is a very ambitious target - and will take many years to achieve. People are slow to adopt new treatments and it takes time to penetrate a conservative market segment.
It will take time to get the treatment approved for reimbursement from insurance companies and public health authorities.
In addition - other competitive treatments and technologies will emerge - while this one may not be the answer - new treatment technologies will. http://www.engadget.com/2010/12/02/over-the-counter-spray-on-stem-cell-treatment-could-treat-burns/
So while I am optimistic for the outcome of TIS and I am a long term shareholder - I think this is a long term investment. There will short term profits to be made by market speculators - for sure.
The real returns will take many years to develop and I am not sure your back of the envelope estimates are at all realistic.
It is yet a long journey ahead of us to commercialization and market penetration.
TIS Price at posting:
47.9¢ Sentiment: LT Buy Disclosure: Held